# Dermatology

### Conditions

- [Atopic dermatitis](/content/dermatology/atopic-dermatitis/index.html)
- [Psoriasis](/content/dermatology/psoriasis/index.html)
- [Actinic keratosis](/content/dermatology/actinic-keratosis/index.html)
- [Acne](/content/dermatology/acne/index.html)
- Other skin conditions
  - [Onychomycosis](/content/dermatology/onychomycosis/index.html)
  - [Alopecia areata](/content/dermatology/alopecia-areata/index.html)
  - [Keratinocyte cancer](/content/dermatology/keratinocyte-cancer/index.html)
  - [Vitiligo](/content/dermatology/vitiligo/index.html)
  - [Hidradenitis suppurativa](/content/dermatology/hidradenitis-suppurativa/index.html)
  - [Rare skin diseases](/content/dermatology/rare-skin-diseases/index.html)

# Financial Information Materials

## An Accessible Source of Financial Insight

Find all the **essential financial information materials that you might need in order to assess our performance** and understand the context behind our results. We aim to present the information in a structured, practical way so that users can follow our progress throughout the year, form a clear perspective on our financial position, and keep abreast of the factors that shape our strategic direction.

### Investors

#### Stock Information
- [Share performance](/content/investors/stock-information/share-performance/index.html)
- [Share capital & ownership](/content/investors/stock-information/share-capital/index.html)
  - Share and capital structure
  - Share issues
  - Shareholdings
- [Analyst coverage](/content/investors/stock-information/analyst-coverage/index.html)
- [Corporate actions & financing](/content/investors/stock-information/actions-financing/index.html)
  - Takeover bids
  - Dividends
  - Debt issues
- [Financial data](/content/investors/financial-data/results-accounts/index.html)
- [Public periodic information](/content/investors/financial-data/public-information/index.html)
- [Financial information materials](/content/investors/financial-data/information-materials/index.html)
  - Financial data
  - Factsheet
  - Corporate presentations
  - Average period of payment to suppliers

### CNMV Communications

#### Significant Events

#### Inside Information

### Corporate Governance
- [Shareholders annual general meeting](/content/investors/corporate-governance/annual-meeting/index.html)
- [Board of directors](/content/investors/corporate-governance/board-directors/index.html)
- [Board commissions](/content/investors/corporate-governance/board-comissions/index.html)
- [Corporate governance & directors’ remuneration reports](/content/investors/corporate-governance/governance-director/index.html)
- [Agreements between significant shareholders](/content/investors/corporate-governance/agreements/index.html)
- [Corporate rules and policies](/content/investors/corporate-governance/corporate-policies/index.html)

### Corporate Responsibility
- Information security in Almirall

### Our Leadership
- [Management board](/content/investors/leadership/management-board/index.html)

### Reports
- [Annual reports](/content/investors/reports/annual/index.html)

## Regular Financial Updates

We **publish periodic materials that reflect our performance at key points in the year**. These include quarterly reports, summaries of results, and detailed financial datasets that provide a clear breakdown of revenue, expenses, investments, and operational highlights. Our goal is to offer clarity through consistent, reliable reporting.

## Presentations and Analyst Resources

To complement data-based materials, we also share **presentations and resources designed for analysts, investors, and financial stakeholders**. These documents summarize our strategic priorities, explain the context of our performance, and highlight indicators that support long-term forecasting.

## Supporting Well-Informed Decisions

We consider transparency a fundamental part of our relationship with investors. We remain committed to openness, accuracy, and a consistent flow of relevant information.

## Factsheet

Download a company overview including the current share performance, latest news, upcoming investor events, and key financial figures.

- [Company overview PDF 192.9KB](https://blob.almirall.com/files/2026-04/About-Almirall-ENG-1.pdf)
- [Sustainability Snapshot PDF 864.6KB](https://blob.almirall.com/files/2026-04/Almirall-39-s-Sustainability_snapshot_2025.pdf)

## Corporate Presentations

Here, we provide corporate presentations submitted to the analyst and investors community.
- [44th Annual J.P. Morgan Healthcare Conference 2026 PDF 1.2MB](https://blob.almirall.com/files/2026-04/JP-Morgan-2026-vFinal.pdf)
- [Presentation of 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies PDF 1.9MB](https://blob.almirall.com/files/2026-04/Lebri-Presentation-Slides_30032022-1.pdf)

## Average Period of Payment to Suppliers

Information on delays in payments to suppliers CCAA
- [PDF 367.2KB](https://blob.almirall.com/files/2026-04/Information-on-deferrals-of-payments-to-suppliers-CCAA.pdf)
  
Information on delays in payments to suppliers CCAACC
- [PDF 258.9KB](https://blob.almirall.com/files/2026-04/Information-on-deferrals-of-payments-to-suppliers-CCAACC.pdf)